Hologic rejects over $16 billion take-private proposal from TPG and Blackstone, FT reports
|
| 5-day change | 1st Jan Change | ||
| 62.92 USD | +15.92% | | +11.27% | -12.84% |
Published on 05/27/2025 at 13:19
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women’s health. Net sales break down by area of application as follows:
– molecular diagnostics (44.2%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin;
– breast health (37.8%): digital mammography and breast biopsy solutions and systems;
– gynecological surgery (15.9%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures;
– bone health (2.1%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment.
Net sales break down by source of revenue between sales of products (80.8%) and services (19.2%).
Net sales are distributed geographically as follows: the United States (75%), Europe (13.2%), Asia-Pacific (6.5%) and others (5.3%).
Buy
Average target price
67.14USD
Spread / Average Target
+23.69%
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
